Yes
[5] [6] 1996 Irinotecan Chemo-therapy £7,852 (€8,921) [7] 2002 ND UGT1A1 Yes [8] 2002 Oxaliplatin Chemo-therapy £18,528 (€21,111) [7] 2002 ND Oncotype DX Yes [9] 2005 Capecitabine Chemo-therapy £6,789 (€7,713) [10] Pembrolizumab is a MoAb that blocks PD-L1 from binding to PD-1 on the T cell allowing an immune response against the tumour All ICERs for UGT1A1 genotyping for guidance of irinotecan dosing were in excess of £1 million (€1 million) and therefore disregarded (see Table 2A ). 
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